

SUPPLEMENTARY MATERIAL

Table S1. Neutralizing titers (NT₅₀) of BriLife® vaccinees against SARS-CoV-2 original virus, variants alpha, beta, and gamma (set 1). Samples that were below

| Vaccinee # | original virus | alpha | beta | gamma |
|--|-----------------------|--------------|-------------|--------------|
| 1 | 241 | 72 | 10 | 321 |
| 2 | 65 | 10 | 44 | 114 |
| 3 | 137 | 54 | 10 | 160 |
| 4 | 197 | 154 | 75 | 228 |
| 5 | 251 | 108 | 34 | 504 |
| 6 | 220 | 49 | 41 | 426 |
| 7 | 240 | 86 | 234 | 349 |
| 8 | 258 | 95 | 60 | 220 |
| 9 | 608 | 836 | 420 | 896 |
| Mean titer | 246 | 163 | 103 | 357 |
| Fold change (relative to original virus) | | 1.5 | 2.4 | 0.7 |

LOD were assigned a value of 10 (half of the LOD).

Table S2. Neutralization titers (NT₅₀) of BriLife® vaccinees against SARS-CoV-2 original virus, delta and omicron variant of concern (set 2). Samples that were below LOD were assigned a value of 10 (half of the LOD).

| Vaccinee # | original virus | delta | omicron |
|--|-----------------------|--------------|----------------|
| 1 | 121 | 85 | 85 |
| 2 | 130 | 66 | 48 |
| 3 | 42 | 149 | 55 |
| 4 | 166 | 85 | 47 |
| 5 | 208 | 210 | 175 |
| 6 | 112 | 80 | 68 |
| 7 | 133 | 104 | 75 |
| 8 | 83 | 10 | 38 |
| 9 | 375 | 383 | 25 |
| 10 | 94 | 10 | 43 |
| 11 | 141 | 172 | 10 |
| 12 | 295 | 273 | 10 |
| 13 | 80 | 78 | 10 |
| Mean titers | 152 | 131 | 53 |
| Fold decrease (relative to original virus) | | 1.2 | 2.9 |

Table S3. Neutralization titers (NT₅₀) of BriLife® vaccinees against rVSV-WT (Indiana serotype) at time zero (T0), 28 days post 1st vaccination (P) and two weeks following 2nd vaccination (P+B). Samples that were below LOD were assigned a value of 10 (half of the LOD).

| Vaccinee # | T0 | P | P+B |
|--------------------|-----------|-----------|------------|
| 1 | 21 | 38 | 62 |
| 2 | 83 | 99 | 202 |
| 3 | 10 | 10 | 72 |
| 4 | 10 | 10 | 10 |
| 5 | 115 | 57 | 52 |
| 6 | 10 | 45 | 10 |
| 7 | 10 | 10 | 10 |
| 8 | 43 | 30 | 45 |
| 9 | 10 | 10 | 59 |
| 10 | 10 | 10 | 10 |
| Mean titers | 32 | 32 | 53 |

Table S4. Neutralizing titers (NT₅₀) of convalescent sera against SARS-CoV-2 original virus, variants alpha, beta, gamma and delta (convalescent set). Samples that were below LOD were assigned a value of half of the LOD.

| Convalescent sera # | original virus | alpha | beta | gamma | delta |
|---|---------------------------|--------------|-------------|--------------|--------------|
| 1 | 541 | 296 | 279 | 423 | 85 |
| 2 | 1385 | 1027 | 760 | 953 | 212 |
| 3 | 758 | 197 | 139 | 333 | 160 |
| 4 | 142 | 177 | 160 | 95 | 79 |
| 5 | 366 | 100 | 107 | 297 | 178 |
| 6 | 323 | 40 | 79 | 269 | 115 |
| 7 | 119 | 41 | 65 | 132 | 39 |
| 8 | 104 | 20 | 66 | 40 | 103 |
| 9 | 123 | 51 | 39 | 50 | 41 |
| Mean titers | 429 | 216 | 188 | 288 | 113 |
| Fold decrease (relative to original virus) | | 2.0 | 2.3 | 1.5 | 3.8 |




Figure S1: Neutralization of alpha, beta, gamma and delta variants by sera from convalescent patients: (a) NT₅₀ of convalescent patients' sera against SARS-CoV-2 original virus, in comparison to (a) alpha, (b) beta, (c) gamma and (d) delta (n=9) variants. Each serum is color coded for all tested viruses. LOD is indicated in each panel (a,c LOD=40; b,d LOD=20). Samples below LOD were assigned a value of half the LOD. Data is presented as mean \pm SEM. Significance was determined by unpaired t-test. p values: 0.2454, 0.1514, 0.4184, 0.0409, for comparison of original virus to alpha, beta, gamma and delta, respectively.